



somalogic

2023 Biostar Research Grant Award Supported by SomaLogic

Biostar and SomaLogic have announced the SomaLogic Sponsored Research Grant Award for China based researchers. The successful applicant will receive high-plex proteomic data from 40 samples submitted for processing at Biostar, China. A full 7000 (7K) protein targets per sample.

Please ask your local Biostar/AccuraMed or SomaLogic representative for more information and instructions on how to enter.

Overview

Somalogic and Biostar Technology Limited in Shanghai are pleased to announce the very first SomaScan 7K proteomic assay research grant award. This award covers delivery of data for 40 samples from a 7K SomaScan Assay from analysis of human serum or plasma.

Program details

Somalogic are encouraging researchers to submit a brief outline of their inventive plans to use the SomaScan Assay 7K from Somalogic in their research. The goal of this program is to assist researchers in China to generate pilot data, which can be used to support their future grant applications, and to promote use of SomaScan Assay 7K as an essential tool for generating high quality proteomic data. Applicants' proposals will be reviewed within 4 weeks of the submission close date (30 November 2023).

Applicants should write a short proposal of 500 words or less, outlining a pilot research project which uses SomaScan Assay 7K. A committee of

SomaLogic staff will review and select the winning applicant based on the following criteria:

- The overall application completeness
- Did the applicant have an original proposal with clear goals and outcomes
- Provide a clear approach and design which matches the goals and outcomes
- How the protein data and analysis are intended to be used
- What are the next steps the researcher intends to take with this additional knowledge
- How does SomaScan 7K data increase insight in to health and disease for their given focus area

Four (4) winners will be selected and be awarded forty (40) samples to be processed on the SomaScan Assay 7K at Biostar in China, together with upstream and downstream support from Somalogic (including discussions with Technical support to validate sample type, discuss limitations, project management team to discuss sample prep/shipping and downstream bioinformatic support).

If applicants have any questions about sample submission requirements, they should email Biostar/AccuraMed at marketing@accuramed.com



Application timelines

Grant announced and advertised via Biostar email database to eligible customers in China.

Announced

September 24, 2023

Open

September 24, 2023

Submission close

November 30, 2023

– late submissions not accepted

Winner announced

January 31, 2024

Samples submitted for processing

March 31, 2024

Data from SomaScan Assay delivered

May 31, 2024

Eligibility criteria

1. The grant program terms and conditions apply.
2. The grant is only open to researchers who are based in China and based at an institution or group where they perform the research.
3. Research teams who already use the SomaScan Assay are not eligible to apply.
4. All submissions must be in English, and comply with the criteria outlined here in this guide.
5. **The samples processed on the SomaScan Assay need to be available and meet certain criteria Handling and Processing guide available in Mandarin and English.**
6. Pilot studies which are creative, bring new insight to health and disease, and have potential to lead to longer term studies are considered highly.
7. For questions about your eligibility or to ask questions about the study you have proposed, please email Biostar/AccuraMed at marketing@accuramed.com
8. Only one application per person is allowed.

Research grant conditions

1. The four (4) successful applicants will receive SomaScan data 7K for each of their 40 samples and include, discussions with Technical support to validate sample

type, discuss limitations, project management team to discuss sample prep/shipping and downstream bioinformatic support. Applicants will own the SomaScan Assay data generated under this grant program.

2. Samples will be run on the SomaScan Assay by Biostar/AccuraMed, an authorized Somalogic site based in China.
3. Application submission deadline is **November 30, 2023**. Any submission made after this date will not be accepted.
4. Successful applicants consent to their name and organization being used for promotional purposes under this grant program.
5. The winner will be announced **January 31, 2024**, by email, social media (WeChat, Facebook, twitter, LinkedIn or others) and be encouraged to present their research in Somalogic marketing activities.
6. For questions about your eligibility or to ask questions about the study you have proposed, please email Biostar/AccuraMed at marketing@accuramed.com
7. The grant is for research purposes only and not to be used for commercial or clinical purposes.
8. The applications will be reviewed by a Somalogic committee and a winner decided by same.
9. Somalogic decision is final on study feasibility.
10. All entrants agree to be contacted by Somalogic for marketing purposes.
11. Special grant terms and conditions apply.

Sample submission

- The grant winners will provide 40 samples to be run on the SomaScan Assay 7K with the output product being data showing signaling for 7000 protein targets.
- Samples must be human plasma or serum. Other sample types may be considered after consultation.
- Samples submitted must be 130 µl volume, have been prepared according to the Somalogic Handling and Processing Guide (please ask for a free copy). Recording, Delivery and labelling will be discussed with the winners.
- Sample submissions, including any associated documentation, cannot include any personal or health information on human subjects. Awardees agree to comply with all applicable laws and regulations with their grant submission and, if awarded, their sample submissions.

TERMS AND CONDITIONS OF THE ACCURAMED RESEARCH GRANT AWARD SUPPORTED BY SOMALOGIC

1. General

The application for the Grant (defined below) is subject to these Terms and Conditions of the AccuraMed Research Grant Award ("Agreement") as supported by SomaLogic. By submitting the completed submission form and provision of the supporting documents to the Grantor (defined below), the Applicant (defined below) is deemed to have agreed and accepted this Agreement, and any amendments hereto. The Grantor reserves the sole and absolute right to withdraw, amend and/or alter any part or the whole of the terms and conditions of this Agreement or any component thereof at any time without giving any prior notice to an Applicant. Any non-compliance with this Agreement may lead to an Applicant being disqualified for consideration, or the application for the Grant cancelled. The parties of the Agreement are the Grantor and the Applicant.

2. Definitions and Interpretation

2.1. In this Agreement, the following words and expressions shall have the following meanings, except where the context otherwise requires:

- (a) **"Agreement"** means all documents setting out the terms and conditions for the award of the Grant by the Grantor to the Applicant, including but not limited to these Terms and Conditions of the SomaLogic Sponsored AccuraMed Research Grant Award, the Research Grant Application Form, the Letter of Award, any annexes, schedules and appendices appended thereto.
- (b) **"Applicable Laws"** means any law (including common law), statute, rule, regulation, directive, code of practice, notice, guideline or requirement issued, adopted, promulgated, implemented or otherwise put into effect by or under the authority of a Governmental Authority of a competent jurisdiction.
- (c) **"Applicant"** means any person or entity who has made an application for the Grant.
- (d) **"Confidential information"** means all communications, information or other materials arising directly and indirectly from the Grant and this Agreement.
- (e) **"Dispute"** means all disputes, claims, questions or differences arising out of or in connection with the Agreement.
- (f) **"Governmental Authority"** means any national, provincial, municipal or local, or any domestic or foreign government, governmental,

regulatory or administrative authority, agency or commission or any court, tribunal, executive, legislative, judicial or arbitral body or self-regulatory organization, or any government owned or controlled entity exercising the aforementioned powers or functions, and shall include any authority exercising a fiscal, revenue, customs or excise function.

- (g) **"Grant"** means the receipt of SomaScan data a specified number of samples and which shall include discussions with: (i) technical support to validate sample type and discuss limitations, and (ii) project management team to discuss sample preparation/shipping and downstream bioinformatic support.
- (h) **"Grantor"** means AccuraMed Biotechnology Co., Limited.,(a.k.a. AccuraMed) in China .
- (i) **"Letter of Award"** means the letter or email confirmation from the Grantor to the Applicant informing the Applicant that the application is successful.
- (j) **"PIPL"** means the Personal Information Protection Law of People's Republic of China.
- (k) **"Personal Data"** means all personal data provided by the Applicant to the Grantor, including the Applicant's name, email address, contact number, institution or entity of employment, and business address.
- (l) **"Recipient"** means any person or entity who has been awarded the Grant by the Grantor.
- (m) **"Sponsor"** means SomaLogic Operating Co., Inc. In the U.S.A.

2.2. In the Agreement:

- (a) All headings or sub-headings are for convenience only and shall not be deemed part of the Agreement.
- (b) the words "hereof", "herein", and "hereunder" and words of similar import, when used in the Agreement, shall refer to the Agreement as a whole and not to any particular provision of the Agreement;
- (c) a reference to a time of day, or day, is to China time and China Day.

3. Eligibility and Selection

3.1. The following eligibility criteria applies with respect to the Grant:

- (a) The application for the Grant is only open to researchers eighteen (18) years and older, who are based in China and are working for a China-based institution or group where the research will be performed. Applicants outside of China are not eligible to participate. Healthcare professionals affiliated with medical institutions or other research organizations having business cooperation with the Grantor are not eligible to participate.
- (b) Research teams who already use the SomaScan Assay are not eligible to apply.
- (c) The Grant is for research purposes only and not to be used for commercial or clinical purposes.
- (d) Only one (1) submission per Applicant.
- (e) All submissions must be in English, and comply with the criteria outlined here and will serve as the basis for selecting a Recipient:
 - i. Applicants should submit a title of the study and brief outline of the inventive plans to use the SomaScan Assay 7K from Somalogic in their research. The goal of this program is to assist researchers in China to generate pilot data, which can be used to support their future grant applications, and to promote use of SomaScan Assay 7K as an essential tool for generating high quality proteomic data.
 - ii. Applicants should write a short proposal of 500 words or less, outlining a pilot research project which uses SomaScan Assay 7K. A committee of Grantor and/or Sponsor staff will review and select the winning applicant based on the following criteria:
 1. The overall application completeness.
 2. Did the applicant have an original proposal with clear goals and outcomes?
 3. Provide a clear approach and design which matches the goals and outcomes.
 4. How the protein data and analysis are intended to be used?
 5. What are the next steps the researcher intends to take with this additional knowledge?
 6. How does SomaScan 7K data increase insight into health and disease for their given focus area?
 7. Samples readiness.

- iii. The outline or proposal submitted by Applicants shall not include any trade secret information or any state secret information.

- (f) The samples processed on the SomaScan Assay need to be available and meet SomaScan Assay sample requirements.

- (g) Four (4) Applicants will be selected as Recipients with two (2) or more Applicants being selected as back-up Recipients in the case of a Lapsed Offer (defined in Section 5.1). In the absence of any Recipient or back-up Recipient, Grantor reserves the right to select other Recipients from the submission pool or re-open the Grant program submission window to additional Applicants.

3.2. For questions about eligibility or to ask questions about the study being proposed, please email Grantor at **marketing@accuramed.com**

3.3. Any decision regarding the eligibility of any application shall be subject to the Grantor's sole discretion.

4. How to Enter

4.1. An interested Applicant must complete the **required submission form**.

4.2. The application submission window shall open and close on the dates outlined in the documentation provided (e.g., grant award description, details and related marketing materials). Any submission submitted after this date will not be accepted. The Grantor reserves the sole and absolute right to end the application for the Grant or any component thereof at any time, without giving prior notice or compensation in cash or in kind. Grantor or Sponsor will attempt to notify Recipients within four (4) weeks after selection of Recipients.

4.3. Upon receipt of an application, the Grantor will assess the application, and may contact the Applicant for more information, if required in the Grantor's sole discretion. Please note that the application may be rejected if the Applicant is not able to provide the Grantor with any requested information.

5. Notification and Disbursement of Grant

5.1. The Grantor will award the Grant to a predetermined number of successful Applicants, who will be informed by way of email of the results, and an invitation to accept the Grant. Such offer to accept the Grant will be valid for five (5) business days from the date of the Grantor's email or phone call/message (unless otherwise indicated in writing). If the awarded applicant's organization requires specific contract with the Authorized site, such as Material Transfer Agreement, Non-Disclosure Agreement or Research Collaboration Agreement, the Grantor and the authorized site need to be notified to proceed into contract process. If such successful Applicant does not accept the offer within this period of time, the offer will be deemed to have lapsed and the Grantor will offer the Grant to another Applicant ("Lapsed Offer"). By accepting the Grant, the successful Applicant also expressly agrees that:

- (a) the Grantor may utilise the Applicant's name or logo in its publications and collaterals for any purpose, including marketing, and will be required to provide presentations on their research in subsequent marketing activities for the Grantor;
- (b) Samples will be run on the SomaScan Assay by Grantor, an authorized Somalogic site based in China, and SomaScan Assay data generated with the Recipient's samples shall belong to the Recipient;
- (c) Samples must be human plasma or serum. Other sample types may be considered after consultation, but there is no guarantee that the Grantor shall accept this. Further, samples submitted must comply with the SomaLogic Handling and Processing Guide available here. Recording, delivery and labelling of the samples will be separately discussed between the Recipients and Grantor;
- (d) Sample submissions, including any associated documentation, cannot include any personal or health information on human subjects. Recipients agree to comply with all applicable laws and regulations with their grant submission and, if awarded, their sample submission;
- (e) It will provide such identification documents or further information as required by the Grantor in its sole discretion to verify and check the identity of the Applicant;
- (f) The Grant is non-transferable.

5.2. Unsuccessful Applicants will be notified but no appeals will be accepted.

5.3. The Grantor's obligations under this Agreement are contingent upon the Recipient's compliance with this Agreement.

6. General Obligations

- 6.1. The Applicant shall not make guarantees and warranties that would obligate the Grantor to any third parties with regard to the Grant and this Agreement, which shall be deemed void.
- 6.2. The Applicant shall notify the Grantor with documentary proof within two (2) weeks of:
 - (a) any change in its name, control, or legal form;
 - (b) events that affect its capacity to utilise the Grant, or
 - (c) the occurrence of any scenario or conditions that are specified in paragraph 10.2.
- 6.3. By making an application for the Grant, the Applicant expressly agrees that it shall not disparage, defame or discredit the Grantor or Sponsor, or any of their respective affiliates, or engage in any activity which would have the effect of disparaging, defaming or discrediting the Grantor, Sponsor or any of their respective affiliates.

7. Representations and Warranties

- 7.1. The Applicant shall ensure that all representations and warranties made in connection with the Agreement remain true, accurate and complete as long as this Agreement remains in force and effect.
- 7.2. In particular, the Applicant represents and warrants to the Grantor that:
 - (a) The Applicant has the capacity and authority to deliver and perform the obligations under the Agreement;
 - (b) The Applicant has taken, fulfilled and done all actions, conditions and things required in order to enable its entry into this Agreement and to ensure that the obligations under the Agreement are valid, legally binding, and enforceable;
 - (c) Its entry into this Agreement and the performance of its obligations herein are in compliance with all Applicable Laws; and
 - (d) All information, disclosure and statements or representations of fact made in its application, submitted forms, supporting documents, and/or related to the Agreement given by the Applicant or its agents or advisors to the Grantor was, when given, and remains true, accurate and complete in every aspect and is not misleading.
 - (e) All materials, documents and other information provided by or on behalf of the Applicant shall not include any trade secret information or any state secret information.
 - (f) The use of the SomaScan Assay is strictly for research use only and not for diagnosis, health assessment or treatment purposes.

8. Use of Information (Consent and Limitations)

- 8.1. The Applicant shall not use the Grantor's or Sponsor's name, logo, or related credits in discussions with third parties, press releases, or public notifications, without the Grantor's prior written consent.
- 8.2. The Grantor and Sponsor shall have the right use and to include references to those Applicants in receipt of a Letter of Award, including the Applicant's name, title, picture, voice or the likeness, and institution and logo in publications, marketing materials, flyers, presentations social media platforms and collaterals, including in any media or other public statement.

9. Indemnity

- 9.1. Subject to prevailing laws, in no event shall the Grantor, Sponsor or any of its employees, officers, directors or subcontractors be liable, and the Applicant hereby unequivocally waives all rights against the Grantor and Sponsor for any actions, proceedings, demands, claims, liabilities, awards, fines, damages, costs or expenses (including any legal and professional fees and expenses awarded against or reasonably incurred by the Grantor or Sponsor), whether special, indirect, incidental, consequential, exemplary or punitive damages, arising from any act or omission in the performance of this Agreement, regardless of the form of action, including in contract or tort (including negligence) from which such damages, costs or expenses may arise, save where such damages, costs or expenses arise due to the gross negligence or wilful default of the Grantor or Sponsor.
- 9.2. Without prejudice to any other rights or remedies which the Grantor or Sponsor may have under law, the Applicant shall be liable for and shall to the fullest extent permitted by the applicable laws indemnify and hold harmless the Grantor and Sponsor and any of its respective employees, officers, directors or subcontractors against all actions, proceedings, demands, claims, liabilities, awards, fines, damages, costs or expenses (including any legal and professional fees and expenses awarded against or reasonably incurred by the Grantor or Sponsor) of any kind which the Grantor or Sponsor may suffer or incur in respect of or in connection with the Grant or arising, directly or indirectly, out of the act, default or omission of the Applicant, its officers, employees and agents, or out of any infringement, breach or non-compliance or non-performance of the obligations hereunder on the Applicant's part to be performed under this Agreement and the Grant.

10. Term and Termination

- 10.1. The Agreement shall commence upon the Applicant's online submission of the application form and, any applicable supporting documents to Grantor, up to the date of any of the following, whichever is the earlier:

- (a) the date of the Lapsed Offer; or
- (b) the period falling twelve (12) months after the acceptance by the Recipient of the Grant.

- 10.2. Without prejudice to any other rights that the Grantor may have under the Agreement, the Grantor may by notice to the Applicant terminate the Agreement with immediate effect or within the timeline stipulated within its notice, upon occurrence of any of the following events:
- (a) the Applicant has breached of any of the terms and conditions contained in the Agreement;
- (b) the making of any false, misleading, or materially inaccurate statements or representations by or on behalf of the Applicant to the Grantor, Sponsor or any third party.
- 10.3. The Grantor, at its sole and absolute discretion, shall have the right to terminate the Agreement without cause with one (1) month's prior written notice to the Applicant.
- 10.4. Upon termination of the Agreement and without prejudice to any accrued rights up to the date of termination, or rights and obligations of the parties under the Agreement which are expressly or impliedly intended to survive termination, all rights and obligations of the parties under the Agreement shall cease, and in particular, the Grantor shall not be required to disburse any part or all of the Grant which has yet to be disbursed as at the date of termination.
- 10.5. Termination or expiry of the Grant and/or the Agreement will not release the Applicant from any liability that, as at the date of termination or expiry, has accrued. The Grantor or Sponsor shall not be liable for any damages loss liability or expenses suffered or incurred by the Applicant or any third party in relation to the termination of the Agreement.
- 10.6. If the Agreement is terminated in accordance to paragraph 10.2, the Grantor shall among other rights have the right to:
- (a) refuse to make disbursement of the Grant to the Applicant; and
- (b) recover from the Applicant part or the full amount of all disbursements made under this Agreement.
- 10.7. The Applicant acknowledges that damages may not be an adequate remedy for breach of the Agreement, and the Grantor shall be entitled to seek remedies of injunction, specific performance and other equitable relief for any threatened or actual breach of the Agreement.

11. Personal Data

- 11.1. By making an application for the Grant or any component thereof, each Applicant consents to the collection, use, disclosure and transfer of the Applicant's Personal Data in accordance with the PDPA by and by and among, as applicable, the Grantor, Sponsor and their respective affiliates for the exclusive purpose of implementing, administering and managing the Applicant's participation in the Grant, including notification and announcement of the Recipient and awarding of the Grant.
- 11.2. The Grantor, Sponsor and their respective affiliates may transfer the Personal Data in accordance with the PDPA amongst themselves as necessary for the purpose of implementation, administration and management of the Applicant's participation in the Grant. The Grantor and its affiliates may each further transfer the personal data to any third parties assisting the Grantor, Sponsor and their respective affiliates in the implementation, administration and management of the Grant. These recipients may be located in Singapore, or elsewhere (including but not limited to the United States of America), and Singapore may have different data privacy laws and protections than the receiving country. The Grantor and its affiliates will ensure that (i) it provides a standard of protection to transferred personal data that is comparable to the protection under the PDPA; and (ii) the overseas recipient is bound by legally enforceable obligations or specified certifications to provide the transferred personal data a standard of protection that is comparable to that under the PIPL.
- 11.3. By making an application for the Grant or any component thereof, the Applicant acknowledges and agrees that the Grantor, Sponsor and their respective affiliates will receive, possess, use, retain and transfer the personal data, in electronic or other form, for the purposes of implementing, administering and managing the Applicant's participation in the Grant, including for marketing and customer follow-up and engagement (e.g., email, telephone, and/or social media) and any requisite transfer of such Personal Data as may be required. The Applicant may, at any time, request access to the Personal Data held by the Grantor with respect to such Applicant, request additional information about the storage and processing of the personal data with respect to such Applicant, recommend any necessary corrections to the Personal Data with respect to the Applicant or object to the processing of personal data, in any case without cost, by contacting the Applicant.
- 11.4. The Grantor may cancel the Applicant's ability to participate in the Grant and, in the Grantor's discretion, the Applicant may forfeit any outstanding awards if the Applicant objects to the processing of the Personal Data as described herein as the processing of the Personal Data is necessary for the performance of the Grant. For

more information on the consequences of to the processing of personal information as described herein, the Applicant may contact the Grantor.

12. Miscellaneous

- 12.1. The Grantor reserves the right to change the terms and conditions of this Agreement from time to time if deemed necessary by the Grantor at its sole discretion.
- 12.2. The Applicant shall not assign novate or transfer any of its rights or obligations under the Agreement.
- 12.3. All notices and communications shall be in writing. Notices by the Grantor to the Applicant shall be deemed to be duly served if made by e-mail to the most recent email address provided by the Applicant to the Grantor, at the time of transmission.
- 12.4. No delay, failure or omission on the part of the Grantor in enforcing any right, power, privilege, claim or remedy under the Agreement shall be deemed to be or be construed as a waiver or variation of such right, power, privilege, claim or remedy.
- 12.5. Nothing contained in this Agreement shall be construed as creating a partnership, joint venture, or association of any kind between the parties or render any party liable for the liabilities of the other party.
- 12.6. Each party shall bear its own legal, professional and other costs and expenses incurred by it in connection with this Agreement and any documents referred to in it.
- 12.7. In the event of any inconsistency amongst the terms set out in the various documents which constitute the Agreement, the following documents shall prevail in the following order:
 - (a) the Grant Sponsorship Program;
 - (b) this Agreement; and
 - (c) the Letter of Award.
- 12.8. Unless expressly provided in this Agreement on the rights and remedies of Sponsor, a person who is not a party to this Agreement shall have no rights to Civil Code 2021 of China to enforce any of the terms.
- 12.9. This Agreement constitutes the entire agreement between the Grantor and the Applicant with respect to its subject matter, and supersedes all prior agreements, understandings, proposals, representations and discussions between the parties, whether verbal or written. There are no understandings, agreements, representations or warranties, expressed or implied, not expressly specified in this Agreement.
- 12.10. The invalidity, unenforceability or illegality of any provision (or part of a provision) of this Agreement

under the Applicable Laws of any jurisdiction or as may be adjudged by a court, shall not affect the validity, enforceability or legality of any other provisions. If any invalid, unenforceable or illegal provision would be valid, enforceable and legal if some part of its were deleted, the provision shall apply with whatever modification as is necessary to give effect to the commercial intention of the parties.

- 12.11 In addition to any provision in the Agreement that is intended to survive termination, paragraphs 7 to 11 shall survive the termination and/or expiry of this Agreement.

This Agreement shall be governed by and construed in accordance with the laws of People's Republic of China. In the event of any Dispute arising between the parties relating to the validity, interpretation, construction or performance of the Agreement, the parties shall use their best endeavours to settle amicably such Dispute by consultation and negotiation. If such efforts taken for such consultation and negotiation shall fail, then such Dispute shall be referred to and finally resolved by arbitration administered by Shanghai sub-commission of China International Economic and Trade Arbitration Commission (CIETAC) under the CIETAC Administered Arbitration Rules in force when the Application for Arbitration is submitted. The seat of arbitration shall be Shanghai. There shall be one arbitrator. The arbitration proceedings shall be conducted in English. The prevailing party shall be entitled to receive from the other party all costs incurred by the arbitration, including but not limited to reasonable attorney fees. The parties hereby submit to the exclusive jurisdiction of the courts of the People's Republic of China.



SL00000883 Rev 1: 2023-09 (A4)

APAC: Biostar (China) Grant Program

SomaLogic® SomaScan® SOMAmer® SomaSignal® and associated logos are trademarks of SomaLogic Operating Co., Inc. and any third-party trademarks used herein are the property of their respective owners. For Research Use Only (RUO). Not intended for diagnostic or patient management purposes. SomaLogic Co, Inc. is accredited to ISO 15189:2012; ISO 27001 and is a CAP-accredited CLIA laboratory. © 2023 SomaLogic Operating Co., Inc. | 2945 Wilderness Pl, Boulder, CO 80301 | Ph 303 625 9000 | www.somallogic.com